IL-13 is a Th2 cytokine that is a known driver of an alternatively activated state in immune cells and is widely applied as an immunomodulatory therapeutic in preclinical studies of SCI [40,41], traumatic brain injury [42], MS [44] and stroke [45,46]. Here, IL13 is linked to myeloid sarcoma.